Key Takeaways
- Growth resumed, but quality is mixed: Revenue returned to sequential growth after Q1's dip, yet the rebound relied heavily on lower-margin consolidation deals that lifted the onsite mix and subcontractor costs.
- Margins fell sharply and will fall further: EBITDA margin dropped to 12.1% from 14.7% QoQ, and a 150 bps wage hike in Q3 will push margins to their absolute trough before any recovery begins.
- The demand environment is frozen, not shrinking: Client budgets are intact but stuck in "hold and wait" mode ahead of the U.S. election, delaying both deal signings and the conversion of transformation projects.
- Management is chasing market share over margins right now: The strategy explicitly accepts lower-margin consolidation deals to gain wallet share, betting that offshoring, utilization, and a digital mix shift will restore margins over time.
- What to watch next quarter: Whether the promised Q4 margin uptick actually begins, the pace of transformation deal conversion once U.S. election uncertainty clears, and any stabilization in the persistently weak Life Sciences and Healthcare verticals.
Demand Environment
- Frozen budgets, not shrinking ones: Client budgets have not been cut, but decision-making is paralyzed by the U.S. election cycle. Customers are financially healthy and simply waiting for clarity before committing to either cost takeouts or transformation investments.
- Deal signings delayed: Some deals were won and papers signed only after the quarter closed, so they missed Q2's TCV count. The election-driven "wait and watch" posture is pushing signings to the right.
- Transformation projects on hold: Once the election cycle ends, transformation projects are expected to return to the table, but with a lag of about six months. Until then, the pipeline is weighted toward vendor consolidation deals.
- Renewals concentrated in H2: The second half of the fiscal year is renewal-heavy, which will shift the order book mix away from net-new work. Management expects to renew everything at healthy margins but is still negotiating.
- Pipeline improving but order book lags: The deal funnel is strong and improving QoQ, yet the order book has not grown well year-on-year. Management dreams of delivering order book growth this year but calls it a "very tall order."
Angan Guha: "Our client budgets have not gone down, but it is on a 'hold and wait' pattern."
Revenue Growth & Vertical Performance
- Broad-based sequential rebound: Most verticals, service lines, and accounts grew QoQ, driven by the initiation of ERP projects that had been deferred in Q1. Core services led as pass-through revenue was much lower than in the prior quarter.
- Manufacturing and E&U led: Both verticals grew 4.7% QoQ. Manufacturing benefited directly from the ramp-up of previously deferred ERP projects.
- BFSI stayed strong: The vertical has now grown for seven consecutive quarters, adding another 1.4% QoQ.
- Digital and Data rebounded: After pressure in preceding quarters, the segment grew 6.6% QoQ, a recovery management wants to sustain as a margin lever.
- Life Sciences remained weak: The vertical has not delivered for three quarters and is expected to stay soft for a couple more before turning the corner.
- Healthcare muted, not structural: Muted growth for two to three quarters stems from specific project and real estate issues in the portfolio, not a sector or client problem. Management expects a strong bounce-back in a couple of quarters.
- Infra dropped on base effect: A sequential decline followed a very strong prior quarter; growth is expected to resume going forward.
- Q3 outlook muted but still growing: Furloughs make Q3 seasonally soft, but management will strive to deliver QoQ growth even if the quantum is small. Q4 growth is expected.
| Vertical | Trend | Commentary |
|---|---|---|
| Manufacturing | ▲ Strong rebound | ERP deferments from Q1 ramped up; up 4.7% QoQ. |
| E&U | ▲ Strong rebound | Up 4.7% QoQ alongside Manufacturing. |
| BFSI | ▲ Continued strength | Seven straight quarters of growth; up 1.4% QoQ. |
| Digital & Data | ▲ Rebound | Up 6.6% QoQ after prior-quarter pressure. |
| Life Sciences | ▼ Weak | Three quarters of underperformance; soft for a couple more. |
| Healthcare | ▼ Muted | Project-specific issues, not sector-wide; strong bounce-back expected. |
| Infra | ▼ Sequential drop | Base effect after strong Q1; growth expected to resume. |
Margins: The Decline and the Recovery Plan
- Q2 margin drop unpacked: EBITDA margin fell to 12.1% from 14.7% in Q1. Q1 included a ₹22.2 crore one-time benefit; like-to-like margins would have been roughly 13% to 13.1%. Of the roughly 100 bps operational decline, half came from a higher onsite mix and half from pricing flexibility on consolidation deals.
- Onsite ratio climbed to ~51%: Consolidation deals are more onsite-centric at inception, and some offshore engagements ended. As these deals mature, work is expected to shift offshore and improve margins.
- Q3 will be the margin trough: A 150 bps wage hike hits in Q3, partially offset by operational recoveries. Management calls Q3 the absolute bottom.
- Recovery from Q4 onward: Every subsequent quarter, Q4 through Q3 of next year, is expected to show margin improvement as deals mature and offshoring kicks in.
- Four margin levers identified: (1) onsite-offshore ratio improvement as engagements mature, (2) utilization improvement from current sub-peak levels, (3) pricing enhancements with existing long-term customers for senior colleagues, (4) quality of revenue improvement through digital business thrust.
- Utilization barely moved: Only a 30 bps increase despite services growth, because consolidation deal revenue came through subcontracting agencies that do not reflect in utilization.
- Desired margin band is far away: Management's target range is 15% to 16.5%. Returning to Q4 FY24 levels of 15.8% to 16.3% may take longer than expected, and management says the market is too volatile to predict a five-quarter timeline.
- Market share vs. margin trade-off explicit: Management is deliberately winning consolidation deals at lower margins to gain wallet share, betting that digital and data growth will balance margins over time.
Angan Guha: "Q3 will be a muted quarter from a margin standpoint, but Q4 onwards, you will see a clear margin improvement."
Deal Dynamics: Consolidation, Renewals, and the Pipeline
- Consolidation deals driving near-term growth: Incremental revenue is coming from vendor consolidation deals that demonstrate wallet share gains in a difficult environment. These require upfront investments and pricing flexibility, pressuring short-to-medium-term margins.
- 50% of order book is net-new or existing-new: This composition gives management confidence that growth momentum will continue, even though the year-on-year order book has not grown well.
- No significant competitive losses: Management says it has not lost a single significant deal to competition, only small ones.
- Renewals concentrated in H2: Renewals typically occur in Q3 and Q4, and H2 renewals will be much larger than H1. Net-new and existing-new business will be a lower percentage of the overall order book in H2.
- Quarterly TCV target of $250 million: Management's goal is to consistently sign $250 million in TCV every quarter. Q3 is a short quarter and unlikely to hit it; Q4 is the target to attempt that number.
- Deal flow trajectory is a multi-quarter story: It will take about six to seven quarters to get the deal flow right, but management believes they are on the right trajectory.
- Sales cycle needs improvement: Management acknowledged this and is investing in it.
Angan Guha: "I am going to go after market share. I am going to win deals at slightly lower margins in the market. But if I am being able to balance that out... I am reasonably confident that I can win market share through the vendor consolidation deals."
People, Delivery & Operating Model
- On-roll headcount declined: Revenue growth was led by an increase in subcontractors, especially for consolidation deals that involve taking over subcontracting parties based onsite.
- Sales and support headcount optimized: The company is focused on support staff optimization while continuing to invest in both general and specialist sales roles. Automation is being used to reduce headcount in existing processes.
- Project Optimus continues: The internal tech transformation project saw headcount ramped up in previous quarters and that ramp continues.
- Execution capability defended: Management expressed full confidence in the team's ability to execute, while noting that underperformers will be replaced.
- Investment in Europe and Asia: Under new leadership for the Rest of the World, the pipeline is starting to shift toward transformation deals rather than vendor consolidation.
Predictability & Long-Term Positioning
- Last two quarters were "very unpredictable": In Q1, customers did not ramp up won deals, so revenue shrank; that revenue came back in Q2. Management attributes this to the nature of infrastructure consolidation deals that require upfront investment before returns materialize.
- More unpredictability expected: Management admits there will be a couple more quarters of unpredictability due to market volatility, but the goal is to be "very predictable over the next 6, 7, 8, 9 quarters."
- Long-term ambition intact: Management is committed to building a long-term sustainable growth-oriented business with a high margin profile, aiming to win market share, deliver growth, and still maintain the margin band.
- Annuity business disclosure coming: The company will provide statistics on annuity business versus project-based revenue in a couple of quarters; it is currently at a foundational level.
Angan Guha: "Even in the future, will there be a couple of quarters where there will be a little bit of unpredictability? It will happen, because the markets are very volatile. But our job now going forward is to be very predictable over the next 6, 7, 8, 9 quarters so that investors like yourself also get a view on it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin trough and recovery | Q3 is absolute margin bottom due to 150 bps wage hike; Q4 onwards clear improvement every subsequent quarter | Q3 FY25 trough; Q4 FY25 recovery start |
| Desired margin band | Return to 15% to 16.5% range | No fixed date; "may take longer than expected" |
| Revenue growth trajectory | Strive for QoQ growth even in seasonally soft Q3; Q4 growth expected | Q3 and Q4 FY25 |
| Quarterly TCV target | Consistently deliver $250 million per quarter | Q4 FY25 is the target to attempt it; Q3 unlikely |
| Life Sciences recovery | Vertical to return to growth after remaining soft | "A couple of quarters" |
| Healthcare bounce-back | Strong recovery expected from project-specific weakness | "A couple of quarters" |
| Transformation deal conversion | Transformation projects back on the table once U.S. election cycle ends | Roughly six-month lag after election clarity |
| Annuity business disclosure | Provide statistics on annuity vs. project-based revenue | "In a couple of quarters" |
| Predictability | Aim to be "very predictable" for investors | Over the next 6 to 9 quarters |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue (USD) | $163.3 million, +2.6% QoQ and +3.2% YoY |
| Revenue (INR) | ₹1,368 crore, +3.1% QoQ and +4.5% YoY |
| EBITDA | $19.7 million, down from $23.4 million in Q1 |
| EBITDA margin | 12.1%, down from 14.7% in Q1; Q1 included a one-time benefit of ₹22.2 crore |
| PAT | $15.2 million (₹127.5 crore) |
| Effective tax rate | 24.9%; full-year ETR expected 25%–26% |
| Cash and bank balance | $221.8 million, up 27.8% after $13 million dividend payout |
| Operating cash flow | $12.9 million |
| Quarterly collections | $176 million, highest in the last six quarters |
| DSO | ~58 days, up QoQ due to collections shifting into early October |
| Interim dividend | ₹2.50 per share |
| Top 5 accounts revenue contribution | 36.7% of total revenues, grew 3.9% QoQ |
| Top 10 accounts revenue contribution | 52.5% of total revenues, grew 2.4% QoQ |
| Top 20 accounts revenue contribution | 64.9% of total revenues, grew 2.3% QoQ |
| Manufacturing vertical growth | +4.7% QoQ |
| Energy and Utilities vertical growth | +4.7% QoQ |
| BFSI vertical growth | +1.4% QoQ |
| ERP business growth | +4.3% QoQ |
| Digital and Data business growth | +6.6% QoQ |
| Onsite revenue ratio | ~51%, up from ~46%–48% in prior quarters |
| Half-year deal signings | ~$300 million, lower than prior year |
| Win ratio | 30%–32%; aspiration is 35%–38% |
| Net new and existing new deal mix | ~50% of order book |
| Voluntary attrition | Not stated |
| Utilization | +30 bps QoQ |
| Salary hike impact expected in Q3 | 150 bps margin dent |
| Core services underlying growth | ~4.5% (per an analyst's math, adjusting for pass-through reduction) |
| Like-to-like EBITDA margin (excl. Q1 one-off) | ~13%–13.1% (per an analyst's math) |
| Operational margin contraction (excl. one-off) | ~100 bps (per an analyst's math) |
| U.S. revenue share | 86%–87% of total business |
| Vendor consolidation deal size range | $10 million to $30 million |
| Target quarterly deal signings | $250 million |
| FY24 TCV growth | +1% YoY |